share_log

Morgan Stanley Maintains Underweight on 4D Molecular Therapeutics, Lowers Price Target to $6

Benzinga ·  Jan 13 16:15  · Ratings

Morgan Stanley analyst Judah Frommer maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Underweight and lowers the price target from $8 to $6.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment